*Please scroll down to the bottom of the page for the final deliverable.
What if you could treat the disease and not just the symptoms?
Neurodegenerative diseases such as Parkinson's, Alzheimer's, and Huntington's disease are distinctly different, but arise through a similar defect.
High levels of specific protein misfolding and aggregation.
While there are symptomatic treatments that can alleviate symptoms for these diseases
There are currently no FDA-approved disease modifying therapies
That address the underlying problem of misfolded and aggregated protein
And slow, stop, or reverse the disease process.
Scientists at Neuropore Therapies are working to change this situation.
Through structure-based drug design processes
Neuropore Therapies has identified novel small molecule compounds
That prevent aggregation of misfolded proteins
Or that promote autophagy, the process by which cells normally clear protein aggregates, addressing the biological mechanism of these challenging diseases.
Our most advanced compound, NPT200-11
A disease-modifying treatment intended for Parkinson's disease
Began Phase 1 clinical trials in 2015.
It serves as only one example of our scientific expertise.
And our commitment to treating these diseases with unmet medical need.
Realize dreams through innovation. Overcome treatment limitations with us. Come explore solutions with us as a partner.